{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 470635574
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = u
| target = [[CD4]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 652153-01-0
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = HG3L8885M0
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06356
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight = 147 kg/mol
}}
'''Zanolimumab''' (expected trade name '''HuMax-CD4'''<ref>[http://www.genmab.com/PressCentre/ArchivedNewsReleases/2000/GenmabInitiatesPhaseIIStudyWithHuMax-CD4/Language/English.aspx Genmab initiates Phase II Study with HuMax-CD4] {{webarchive |url=https://web.archive.org/web/20080516135546/http://www.genmab.com/PressCentre/ArchivedNewsReleases/2000/GenmabInitiatesPhaseIIStudyWithHuMax-CD4/Language/English.aspx |date=May 16, 2008 }}</ref>) is a [[human]] [[monoclonal antibody]] and an [[immunosuppressive drug]]. It is being developed for the treatment of [[rheumatoid arthritis]], [[psoriasis]], [[melanoma]],<ref>{{cite web|url=http://www.tenxbiopharma.com/development.shtml |title=Archived copy |accessdate=August 20, 2010 |deadurl=yes |archiveurl=https://web.archive.org/web/20100411114420/http://www.tenxbiopharma.com/development.shtml |archivedate=April 11, 2010 }}</ref> cutaneous and peripheral [[T-cell lymphoma]].<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/zanolimumab.doc Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab], ''American Medical Association''.</ref><ref>{{ClinicalTrialsGov|NCT00042406|Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker}}</ref> The drug is currently undergoing Phase II trials.<ref>{{cite web|title=Status of clinical trials for Zanolimumab|url=http://clinicaltrials.gov/search/intervention=Zanolimumab|accessdate=6 November 2011}}</ref>

== References ==
<references/>

{{immunosuppressants}}
{{Monoclonals for immune system}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}